Incyte Corporation


Prices are adjusted according to historical splits.

Incyte Corporation Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$13.95 billion
Book Value:
Revenue TTM:
$3.47 billion
Operating Margin TTM:
Gross Profit TTM:
$1.59 billion
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Incyte Corporation had its IPO on 1993-11-04 under the ticker symbol INCY.

The company operates in the Healthcare sector and Biotechnology industry. Incyte Corporation has a staff strength of 2,324 employees.

Stock update

Shares of Incyte Corporation opened at $61.5 at the start of the last trading session i.e. 2023-06-03.

The stocks traded within a range of $61.42 - $62.6, and closed at $62.54.

This is a +1.67% increase from the previous day's closing price.

A total volume of 1,760,400 shares were traded at the close of the day’s session.

In the last one week, shares of Incyte Corporation have slipped by -2.71%.

Incyte Corporation's Key Ratios

Incyte Corporation has a market cap of $13.95 billion, indicating a price to book ratio of 3.8229 and a price to sales ratio of 5.4924.

In the last 12-months Incyte Corporation’s revenue was $3.47 billion with a gross profit of $1.59 billion and an EBITDA of $575.70 million. The EBITDA ratio measures Incyte Corporation's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Incyte Corporation’s operating margin was 14.47% while its return on assets stood at 5.78% with a return of equity of 7.79%.

In Q1, Incyte Corporation’s quarterly earnings growth was a negative -42.7% while revenue growth was a positive 10.3%.

Incyte Corporation’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $1.45 per share while it has a forward price to earnings multiple of 14.9477 and a PEG multiple of 0.4657. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Incyte Corporation’s profitability.

Incyte Corporation stock is trading at a EV to sales ratio of 3.8964 and a EV to EBITDA ratio of 18.6307. Its price to sales ratio in the trailing 12-months stood at 5.4924.

Incyte Corporation stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$5.80 billion
Total Liabilities
$1.08 billion
Operating Cash Flow
Capital Expenditure
$11.91 million
Dividend Payout Ratio

Incyte Corporation ended 2023 with $5.80 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $5.80 billion while shareholder equity stood at $4.46 billion.

Incyte Corporation ended 2023 with $0 in deferred long-term liabilities, $1.08 billion in other current liabilities, 223000.00 in common stock, $-415511000.00 in retained earnings and $155.59 million in goodwill. Its cash balance stood at $2.82 billion and cash and short-term investments were $3.11 billion. The company’s total short-term debt was $3,149,000 while long-term debt stood at $0.

Incyte Corporation’s total current assets stands at $4.11 billion while long-term investments were $128.31 million and short-term investments were $291.66 million. Its net receivables were $623.79 million compared to accounts payable of $55.63 million and inventory worth $157.56 million.

In 2023, Incyte Corporation's operating cash flow was $-28559000.00 while its capital expenditure stood at $11.91 million.

Comparatively, Incyte Corporation paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Incyte Corporation stock is currently trading at $62.54 per share. It touched a 52-week high of $86.29 and a 52-week low of $86.29. Analysts tracking the stock have a 12-month average target price of $82.24.

Its 50-day moving average was $69.31 and 200-day moving average was $74.39 The short ratio stood at 3.55 indicating a short percent outstanding of 0%.

Around 153.2% of the company’s stock are held by insiders while 9651% are held by institutions.

Frequently Asked Questions About Incyte Corporation

The stock symbol (also called stock or share ticker) of Incyte Corporation is INCY

The IPO of Incyte Corporation took place on 1993-11-04

Similar Industry Stocks (Biotechnology)

Last Price
Symphony Limited (SYMPHONY)

Most Active

Last Price
Zomato Limited (ZOMATO)
Tesla Inc (TSLA)
Yes Bank Limited (YESBANK)

Top Gainers

Last Price
AEye Inc (LIDRW)

Top Losers

Last Price


Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.


1801 Augustine Cut-Off, Wilmington, DE, United States, 19803